Melanotan II: Regulatory Bans, Adverse Events, and Documented Dangers

Melanotan II (MT-II) is a cyclic synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It was developed in the 1980s at the University of Arizona as a potential treatment for erythropoietic protoporphyria, a sun-sensitivity disorder. It was never approved for any medical use. Despite that, it has circulated as an unlicensed "tanning injection" for decades, sold online under names like "Melanotan 2," "MT-2," and the "Barbie drug."

Multiple regulatory agencies have issued formal warnings against Melanotan II: the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Australia's Therapeutic Goods Administration (TGA). Adverse events ranging from mole changes to deaths have been reported to these agencies. This article reviews the documented safety record.

Regulatory Warnings and Enforcement Actions

The MHRA has been among the most active regulators in warning the public about Melanotan products. Key enforcement milestones:

• MHRA 2009: First consumer warning published about unlicensed melanocortin tanning products, noting they are not authorized for human use and have not been assessed for safety or quality.
• MHRA 2012: Drug Safety Update specifically warned that Melanotan products are illegal in the UK, can cause serious harm, and have been the subject of adverse event reports including nausea, facial flushing, unintended erections, changes to existing moles, and new moles.
• MHRA ongoing: The MHRA continues to receive and investigate adverse event reports related to Melanotan products. Sale and supply of Melanotan II as a medicinal product without a licence is a criminal offence under the Medicines Act 1968.
• FDA warnings: The FDA has taken enforcement action against multiple U.S. companies selling Melanotan products, issuing import alerts and warning letters citing unapproved drug status.
• Australia TGA: Listed Melanotan I and II as Schedule 4 prescription-only substances; unauthorized supply carries criminal penalties.

Documented Adverse Events

Melanotan II acts on multiple melanocortin receptor subtypes (MC1R through MC5R), which are distributed throughout the body: skin, brain, reproductive organs, adrenal glands, immune cells. Broad receptor activation produces a correspondingly broad range of adverse effects:

• Nausea and vomiting: The most commonly reported adverse effect, occurring in the majority of users, particularly during initial doses. Severity can range from mild nausea to vomiting requiring medical attention.
• Facial flushing and yawning: Characteristic cholinergic-like response reported almost universally. Often accompanied by warmth and spontaneous yawning.
• Spontaneous and prolonged erections (priapism): MT-II strongly activates MC4R, which mediates penile erections via hypothalamic pathways. Cases of priapism (erection lasting >4 hours) requiring emergency medical intervention have been reported. Priapism is a urological emergency that, if untreated, can cause permanent erectile dysfunction.
• Changes to existing moles and new mole formation: MC1R activation drives melanogenesis and melanocyte proliferation. Multiple case reports document the rapid darkening and growth of pre-existing naevi (moles) following Melanotan use, consistent with expected pharmacology.
• Melanoma development: Several published case reports describe the development of malignant melanoma associated with Melanotan II use. A 2014 BMJ case report described a patient who developed melanoma following MT-II injections; the authors concluded that MT-II-stimulated melanocyte proliferation had likely accelerated the malignant transformation of an existing naevus.
• Cardiovascular effects: Increases in blood pressure and heart rate have been reported, related to sympathomimetic properties. Melanocortin receptors are expressed in cardiovascular tissue.
• Psychiatric effects: Reports include unusual mood changes, dysphoria, and exacerbation of psychiatric symptoms — consistent with CNS melanocortin receptor activation.
• Hyperpigmentation of unexpected areas: Unwanted darkening of the face, lips, palms, soles, and genitals has been extensively documented.

We strongly advise the public not to use Melanotan products. They are unlicensed medicines and can cause serious harm. Changes to moles should always be assessed urgently by a doctor.

— Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update, 2012

Melanoma Risk: The Core Safety Concern

The relationship between Melanotan II and melanoma risk is the most serious concern associated with the compound, and it's mechanistically plausible rather than merely speculative. Alpha-MSH (the endogenous peptide MT-II mimics) normally regulates melanocyte activity. Melanocytes are the cells that, when they undergo malignant transformation, become melanoma.

MT-II is far more potent and metabolically stable than natural α-MSH. Prolonged, supraphysiological stimulation of MC1R could theoretically push benign naevi (moles), particularly dysplastic ones, toward malignant transformation, or promote the growth of micrometastatic melanoma that might otherwise remain dormant. Individuals with a large number of moles, a history of severe sunburn, or a personal or family history of melanoma face the highest theoretical risk.

MT-II also promotes sunbathing behavior, which is the whole reason people take it. The added UV exposure compounds the melanoma risk. The MHRA has specifically highlighted that the combination of MC1R-driven melanocyte activation plus increased UV exposure is particularly concerning.

Deaths Associated with Melanotan Products

The MHRA and other regulators have received reports of deaths in the context of Melanotan product use. Establishing direct causation is difficult in post-market surveillance, particularly when products are of unknown purity, administered without medical oversight, and deaths may involve multiple contributing factors. The regulatory conclusion across agencies has been consistent: the risk-benefit profile of Melanotan products, for any indication, is unacceptable.

Causes of deaths reported in the context of Melanotan use have included cardiovascular events and, in some cases, melanoma that may have been accelerated by use. Non-sterile injection technique has also led to serious systemic infections that can be life-threatening. In each jurisdiction where Melanotan is sold illegally, emergency physicians have reported treating serious adverse events in users — and those cases represent only those who sought treatment.

The "Tanning Injection" Market: Contamination and Uncontrolled Dosing

Melanotan II products circulate in an entirely unregulated market. Independent laboratory analysis of MT-II products has found wildly variable actual peptide content, frequent bacterial contamination, and, in some cases, peptides other than MT-II. Users typically self-inject with no medical supervision, no baseline mole mapping, and no post-use monitoring. This context dramatically amplifies whatever intrinsic risks MT-II itself poses.

Summary: Why Regulatory Agencies Are Consistent

Every major regulatory agency that has evaluated Melanotan II has reached the same conclusion: the compound should not be used by consumers. The combination of a broad adverse effect profile, serious melanoma risk supported by both case reports and mechanistic plausibility, documented deaths in the context of use, no approved therapeutic indication, and a completely unregulated supply chain places MT-II among the higher-risk compounds in the research peptide space.

This is distinct from other research peptides where the primary concern is simply insufficient human data. With Melanotan II, there are affirmative safety signals from regulatory agencies, published case reports of serious harm, and a pharmacological mechanism that predicts harm in vulnerable individuals. Anyone currently using MT-II and noticing changes to moles or skin lesions should seek medical evaluation promptly.

Questions and answers

Is Melanotan II legal?

Not as a medicinal product in the United Kingdom. Sale and supply of Melanotan II as a medicinal product without a licence is a criminal offence under the Medicines Act 1968. The MHRA first warned consumers in 2009 and issued a Drug Safety Update in 2012, and the FDA has taken enforcement action against multiple suppliers.

Why is melanoma the core safety concern?

Because the concern is mechanistically plausible rather than merely speculative. Melanotan II mimics alpha-MSH, which normally regulates melanocyte activity, and is far more potent and metabolically stable. Prolonged supraphysiological MC1R stimulation could in theory push benign naevi, particularly dysplastic ones, toward malignant transformation, or promote growth of micrometastatic melanoma that might otherwise remain dormant.

What adverse events have been reported?

Nausea and vomiting, the most commonly reported effect and occurring in the majority of users. Facial flushing and spontaneous yawning, reported almost universally. Prolonged erections, with cases of priapism lasting over four hours requiring emergency medical intervention. The MHRA's 2012 update also cited changes to existing moles and the appearance of new moles.

How does Melanotan II differ in risk from other research peptides?

With most research peptides the primary concern is simply insufficient human data. With Melanotan II there are affirmative safety signals from regulatory agencies, published case reports of serious harm, and a pharmacological mechanism that predicts harm in vulnerable individuals. Anyone using it who notices changes to moles or skin lesions should seek medical evaluation promptly.